* Industry diversification based on Moody's industry classification. Measured as the fair value of investments for each category against the total fair value of all investments. Totals may not sum due to rounding.
A balanced portfolio built on the cornerstones of diversification and selectivity
Anchored in senior secured loans, NCDL has built a scaled and diversified portfolio by industry, investment type and portfolio company. Selectivity, diversification and rigorous underwriting are key to our investment philosophy, enabling strong credit performance since inception.
Portfolio holdings
Top ten positions
Represents the top ten positions in NCDL based on Fair Value as of September 30, 2025
| Company | Fair value ($ in thousands) | Industry | Asset Types | Pricing1 |
|---|---|---|---|---|
| Affinity Hospice Intermediate Holdings, LLC | 5,260,855 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.75% |
| QHR Health, LLC | 3,183,175 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
| QHR Health, LLC | 3,183,175 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
| Promptcare Infusion Buyer, Inc. | 1,253,006 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 6.00% |
| NP/BF Holdings, L.P. | 1,000,000 | Healthcare & Pharmaceuticals | Equity Investments | |
| Swoop Intermediate III, Inc. | 9,237 | Healthcare & Pharmaceuticals | Revolving Loan | S + 4.50% |
| Swoop Intermediate III, Inc. | 25,625 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 4.50% |
| Real Chemistry Intermediate III, Inc. | 1,262,829 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 4.50% |
| Bluebird PM Buyer, Inc. | 8,435,426 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.75% |
| Wellspring Pharmaceutical Corporation | 1,543,421 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.00% |
| Anne Arundel Dermatology Management, LLC | 1,704,350 | Healthcare & Pharmaceuticals | Subordinated Debt (Delayed Draw) | 12.75% (PIK) |
| Tidi Legacy Products, Inc. | 15,403,567 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.50% |
| WE Select Fund 3, L.P. | 483,000 | Healthcare & Pharmaceuticals | Equity Investments | |
| TBRS, Inc. | 8,982,005 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.75% |
| MDC Intermediate Holdings II, LLC (Mosaic Dental) | 1,791,996 | Healthcare & Pharmaceuticals | Subordinated Debt | 14.25% (PIK) |
| Bridges Consumer Healthcare Intermediate LLC | 5,682,268 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
| MDC Intermediate Holdings II, LLC (Mosaic Dental) | 477,609 | Healthcare & Pharmaceuticals | Subordinated Debt (Delayed Draw) | 14.25% (PIK) |
| Wellspring Pharmaceutical Corporation | 7,256,874 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.00% |
| Tidi Legacy Products, Inc. | 40,849 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 4.50% |
| Sandlot Buyer, LLC (Prime Time Healthcare) | 9,079,996 | Healthcare & Pharmaceuticals | First Lien Debt | S + 6.25% |
| Lavie Group, Inc. | 2,722,596 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.00% |
| Sandlot Buyer, LLC (Prime Time Healthcare) | 7,710,205 | Healthcare & Pharmaceuticals | First Lien Debt | S + 6.25% |
| YI, LLC (Young Innovations) | 15931948.91 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.75% |
| AB Centers Acquisition Corporation (Action Behavior Centers) | 1,458,375 | Healthcare & Pharmaceuticals | First Lien Debt | S + 5.25% |
| Bridges Consumer Healthcare Intermediate LLC | 2,154,869 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
| Bridges Consumer Healthcare Intermediate LLC | (73,294) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
| AB Centers Acquisition Corporation (Action Behavior Centers) | 997,620 | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 5.25% |
| ACP Maverick Holdings, Inc.Ê | (32,852) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 4.75% |
| ACP Maverick Holdings, Inc.Ê | 16,134,724 | Healthcare & Pharmaceuticals | First Lien Debt | S + 4.75% |
| TBRS, Inc. | (22,339) | Healthcare & Pharmaceuticals | First Lien Debt (Delayed Draw) | S + 4.75% |
1. The majority of the investments bear interest at rates that may be determined by reference to Secured Overnight Financing Rate ("SOFR" or "S"), which reset monthly or quarterly. For each such investment, the Company has provided the spread over SOFR and the current contractual interest rate in effect at September 30, 2025. As of September 30, 2025, rates for 1M S, 3M S, 6M S, 12M S ("SOFR") are 4.13%, 3.98%, 3.85%, and 3.66% respectively. Certain investments are subject to a SOFR floor or may utilize an alternative reference rate such as U.S. Prime Rate (“P”). For fixed rate loans, a spread above a reference rate is not applicable.